These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Integrin αVβ3 silencing sensitizes malignant glioma cells to temozolomide by suppression of homologous recombination repair. Christmann M; Diesler K; Majhen D; Steigerwald C; Berte N; Freund H; Stojanović N; Kaina B; Osmak M; Ambriović-Ristov A; Tomicic MT Oncotarget; 2017 Apr; 8(17):27754-27771. PubMed ID: 27487141 [TBL] [Abstract][Full Text] [Related]
3. Estrogen receptor beta enhances chemotherapy response of GBM cells by down regulating DNA damage response pathways. Zhou M; Sareddy GR; Li M; Liu J; Luo Y; Venkata PP; Viswanadhapalli S; Tekmal RR; Brenner A; Vadlamudi RK Sci Rep; 2019 Apr; 9(1):6124. PubMed ID: 30992459 [TBL] [Abstract][Full Text] [Related]
4. Are There Thresholds in Glioblastoma Cell Death Responses Triggered by Temozolomide? He Y; Kaina B Int J Mol Sci; 2019 Mar; 20(7):. PubMed ID: 30925722 [TBL] [Abstract][Full Text] [Related]
5. Nuclear factor I A promotes temozolomide resistance in glioblastoma via activation of nuclear factor κB pathway. Yu X; Wang M; Zuo J; Wahafu A; Mao P; Li R; Wu W; Xie W; Wang J Life Sci; 2019 Nov; 236():116917. PubMed ID: 31614149 [TBL] [Abstract][Full Text] [Related]
6. Lysine-specific histone demethylase 1A (KDM1A/LSD1) inhibition attenuates DNA double-strand break repair and augments the efficacy of temozolomide in glioblastoma. Alejo S; Palacios BE; Venkata PP; He Y; Li W; Johnson JD; Chen Y; Jayamohan S; Pratap UP; Clarke K; Zou Y; Lv Y; Weldon K; Viswanadhapalli S; Lai Z; Ye Z; Chen Y; Gilbert AR; Suzuki T; Tekmal RR; Zhao W; Zheng S; Vadlamudi RK; Brenner AJ; Sareddy GR Neuro Oncol; 2023 Jul; 25(7):1249-1261. PubMed ID: 36652263 [TBL] [Abstract][Full Text] [Related]
7. IKBKE enhances TMZ-chemoresistance through upregulation of MGMT expression in glioblastoma. Guo G; Sun Y; Hong R; Xiong J; Lu Y; Liu Y; Lu J; Zhang Z; Guo C; Nan Y; Huang Q Clin Transl Oncol; 2020 Aug; 22(8):1252-1262. PubMed ID: 31865606 [TBL] [Abstract][Full Text] [Related]
8. Temozolomide Induces Senescence and Repression of DNA Repair Pathways in Glioblastoma Cells via Activation of ATR-CHK1, p21, and NF-κB. Aasland D; Götzinger L; Hauck L; Berte N; Meyer J; Effenberger M; Schneider S; Reuber EE; Roos WP; Tomicic MT; Kaina B; Christmann M Cancer Res; 2019 Jan; 79(1):99-113. PubMed ID: 30361254 [TBL] [Abstract][Full Text] [Related]
9. Bortezomib inhibits growth and sensitizes glioma to temozolomide (TMZ) via down-regulating the FOXM1-Survivin axis. Tang JH; Yang L; Chen JX; Li QR; Zhu LR; Xu QF; Huang GH; Zhang ZX; Xiang Y; Du L; Zhou Z; Lv SQ Cancer Commun (Lond); 2019 Dec; 39(1):81. PubMed ID: 31796105 [TBL] [Abstract][Full Text] [Related]
10. Artesunate enhances the therapeutic response of glioma cells to temozolomide by inhibition of homologous recombination and senescence. Berte N; Lokan S; Eich M; Kim E; Kaina B Oncotarget; 2016 Oct; 7(41):67235-67250. PubMed ID: 27626497 [TBL] [Abstract][Full Text] [Related]
11. ZSTK474 Sensitizes Glioblastoma to Temozolomide by Blocking Homologous Recombination Repair. Jiao W; Zhu S; Shao J; Zhang X; Xu Y; Zhang Y; Wang R; Zhong Y; Kong D Biomed Res Int; 2022; 2022():8568528. PubMed ID: 35872860 [TBL] [Abstract][Full Text] [Related]
12. The TNF receptor family member Fn14 is highly expressed in recurrent glioblastoma and in GBM patient-derived xenografts with acquired temozolomide resistance. Hersh DS; Harder BG; Roos A; Peng S; Heath JE; Legesse T; Kim AJ; Woodworth GF; Tran NL; Winkles JA Neuro Oncol; 2018 Sep; 20(10):1321-1330. PubMed ID: 29897522 [TBL] [Abstract][Full Text] [Related]
13. DNA-methylation-mediated activating of lncRNA SNHG12 promotes temozolomide resistance in glioblastoma. Lu C; Wei Y; Wang X; Zhang Z; Yin J; Li W; Chen L; Lyu X; Shi Z; Yan W; You Y Mol Cancer; 2020 Feb; 19(1):28. PubMed ID: 32039732 [TBL] [Abstract][Full Text] [Related]
14. Molecular Dosimetry of Temozolomide: Quantification of Critical Lesions, Correlation to Cell Death Responses, and Threshold Doses. Stratenwerth B; Geisen SM; He Y; Beltzig L; Sturla SJ; Kaina B Mol Cancer Ther; 2021 Oct; 20(10):1789-1799. PubMed ID: 34253592 [TBL] [Abstract][Full Text] [Related]
15. Downregulation of BRCA1-BRCA2-containing complex subunit 3 sensitizes glioma cells to temozolomide. Chai KM; Wang CY; Liaw HJ; Fang KM; Yang CS; Tzeng SF Oncotarget; 2014 Nov; 5(21):10901-15. PubMed ID: 25337721 [TBL] [Abstract][Full Text] [Related]
16. Extracellular vesicles derived from hypoxic glioma stem-like cells confer temozolomide resistance on glioblastoma by delivering miR-30b-3p. Yin J; Ge X; Shi Z; Yu C; Lu C; Wei Y; Zeng A; Wang X; Yan W; Zhang J; You Y Theranostics; 2021; 11(4):1763-1779. PubMed ID: 33408780 [No Abstract] [Full Text] [Related]
17. Extracellular vesicles carry miR-27a-3p to promote drug resistance of glioblastoma to temozolomide by targeting BTG2. Chen L; Li Z; Hu S; Deng Q; Hao P; Guo S Cancer Chemother Pharmacol; 2022 Feb; 89(2):217-229. PubMed ID: 35039898 [TBL] [Abstract][Full Text] [Related]
18. Synergistic Suppression of Glioblastoma Cell Growth by Combined Application of Temozolomide and Dopamine D2 Receptor Antagonists. Liu Z; Jiang X; Gao L; Liu X; Li J; Huang X; Zeng T World Neurosurg; 2019 Aug; 128():e468-e477. PubMed ID: 31048057 [TBL] [Abstract][Full Text] [Related]
19. Prognostic implications of the subcellular localization of survivin in glioblastomas treated with radiotherapy plus concomitant and adjuvant temozolomide. Saito T; Sugiyama K; Takeshima Y; Amatya VJ; Yamasaki F; Takayasu T; Nosaka R; Muragaki Y; Kawamata T; Kurisu K J Neurosurg; 2018 Mar; 128(3):679-684. PubMed ID: 28430038 [TBL] [Abstract][Full Text] [Related]
20. 20(S)-ginsenoside-Rg3 reverses temozolomide resistance and restrains epithelial-mesenchymal transition progression in glioblastoma. Chen Z; Wei X; Shen L; Zhu H; Zheng X Cancer Sci; 2019 Jan; 110(1):389-400. PubMed ID: 30431207 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]